| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | 
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Total Revenue | 43.98B | 44.32B | 40.02B | 27.09B | 19.46B | 20.56B | 
| Gross Profit | 36.18B | 37.05B | 32.53B | 20.54B | 13.62B | 15.24B | 
| EBITDA | 19.12B | 21.44B | 17.51B | 9.67B | 2.60B | 6.07B | 
| Net Income | 16.98B | 18.85B | 13.88B | 7.15B | 1.70B | 4.41B | 
| Balance Sheet | ||||||
| Total Assets | 0.00 | 86.31B | 69.06B | 56.57B | 51.09B | 47.92B | 
| Cash, Cash Equivalents and Short-Term Investments | 24.97B | 24.97B | 17.78B | 11.25B | 7.60B | 8.18B | 
| Total Debt | 0.00 | 2.79B | 3.86B | 1.76B | 4.32B | 2.84B | 
| Total Liabilities | -76.12B | 10.19B | 10.53B | -34.80B | 8.46B | 6.68B | 
| Stockholders Equity | 76.12B | 76.07B | 58.53B | 48.74B | 42.64B | 41.22B | 
| Cash Flow | ||||||
| Free Cash Flow | 0.00 | 14.28B | 8.72B | 6.43B | -1.96B | 442.00M | 
| Operating Cash Flow | 0.00 | 16.97B | 12.12B | 8.49B | 465.00M | 2.99B | 
| Investing Cash Flow | 0.00 | -14.14B | -10.33B | -4.77B | -53.00M | -1.03B | 
| Financing Cash Flow | 0.00 | -2.11B | -2.47B | -3.63B | 348.00M | -1.86B | 
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth | 
|---|---|---|---|---|---|---|---|
| ― | ₹147.98B | 8.72 | ― | 0.60% | 4.14% | 3.72% | |
| ― | ₹80.16B | 22.89 | ― | 0.43% | 16.94% | 4.90% | |
| ― | ₹141.02B | 54.30 | ― | 0.22% | 14.82% | 19.38% | |
| ― | ₹175.16B | 37.13 | ― | 0.45% | 8.12% | -16.64% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | ₹522.88B | 69.69 | ― | 0.13% | 10.99% | ― | 
Natco Pharma Limited has submitted a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ending September 30, 2025. This certificate confirms that securities received for dematerialization have been processed correctly, with updates made to the depositories’ records, ensuring compliance with regulatory requirements. This announcement underscores Natco Pharma’s commitment to maintaining regulatory compliance and transparency in its operations, which is crucial for its stakeholders and market reputation.
Natco Pharma Limited announced that its pharmaceutical division in Kothur, Hyderabad, has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA), classifying the facility as ‘Voluntary Action Indicated’ (VAI). This classification indicates that the FDA inspection found some issues that need correction but are not significant enough to warrant regulatory action. The VAI status is a positive outcome for Natco Pharma as it allows the company to continue its operations without major disruptions, potentially enhancing its credibility and market position in the pharmaceutical industry.
Natco Pharma Limited has announced the publication of its 42nd Annual General Meeting details in prominent newspapers, Financial Express and Nava Telangana, as part of regulatory compliance. This announcement underscores the company’s commitment to transparency and adherence to regulatory requirements, which may enhance its reputation among stakeholders and investors.
Natco Pharma Limited’s Board of Directors has declared an interim dividend of Rs. 2 per equity share for the financial year 2025-26, with the record date set for August 19, 2025, and payment commencing on August 26, 2025. Additionally, the Board approved an increase in the company’s authorized capital to Rs. 45 crore, subject to shareholder approval, and announced plans for the 42nd Annual General Meeting to be held via video conference.